title: Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies.
abstract: The vaccinia virus entry/fusion complex (EFC) is comprised of at least eight transmembrane proteins that are conserved in all poxviruses. However, neither the physical structure of the EFC nor the immunogenicity of the individual components has been determined. We prepared soluble forms of two EFC components, A28 and H2, by replacing the transmembrane domain with a signal peptide and adding a polyhistidine tail. The proteins were expressed by baculoviruses, secreted from insect cells, purified by affinity chromatography and used to raise antibodies in rabbits. The antibodies recognized the viral proteins but only the antibody to recombinant A28 bound intact virions and neutralized infectivity. Analyses with a set of overlapping peptides revealed a neutralizing epitope between residues 73 and 92 of A28. Passive immunization of mice with IgG purified from the anti-A28 serum provided partial protection against a vaccinia virus intranasal challenge, whereas IgG from the anti-H2 serum did not.
authors.affiliation: Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3210, USA.
authors.forename: Gretchen E
authors.initials: GE
authors.lastname: Nelson
authors.forename: Jerry R
authors.initials: JR
authors.lastname: Sisler
authors.forename: Dev
authors.initials: D
authors.lastname: Chandran
authors.forename: Bernard
authors.initials: B
authors.lastname: Moss
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology* / Q000627:therapeutic use; D016367:Baculoviridae / Q000235:genetics; D001835:Body Weight; D002846:Chromatography, Affinity; D018604:Epitope Mapping; D005260:Female; D015870:Gene Expression; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D009500:Neutralization Tests; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D014615:Vaccinia / Q000517:prevention & control; D014616:Vaccinia virus / Q000276:immunology* / Q000502:physiology*; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*; D053586:Virus Internalization
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; D014763:Viral Matrix Proteins
references.citation: Virology. 2006 Nov 25;355(2):164-74
references.pmid: 16919703
references.citation: Clin Infect Dis. 2003 Jul 15;37(2):251-71
references.pmid: 12856218
references.citation: J Virol. 2008 Jul;82(13):6244-50
references.pmid: 18417576
references.citation: J Gen Virol. 1990 Nov;71 ( Pt 11):2761-7
references.pmid: 2254756
references.citation: Virology. 1992 May;188(1):217-32
references.pmid: 1566575
references.citation: J Gen Virol. 1971 Oct;13(1):19-25
references.pmid: 5130569
references.citation: J Virol. 1992 Jan;66(1):386-98
references.pmid: 1727494
references.citation: J Virol. 2005 Sep;79(18):11724-33
references.pmid: 16140750
references.citation: Virology. 2006 Feb 5;345(1):231-43
references.pmid: 16256161
references.citation: J Virol. 2005 Nov;79(21):13454-62
references.pmid: 16227266
references.citation: Nat Immunol. 2002 Mar;3(3):265-71
references.pmid: 11828323
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18572-7
references.pmid: 16339313
references.citation: J Virol. 2005 Apr;79(8):4744-54
references.pmid: 15795260
references.citation: Vaccine. 2006 Mar 15;24(12):2065-70
references.pmid: 16337719
references.citation: J Virol. 2004 Mar;78(5):2348-56
references.pmid: 14963131
references.citation: J Virol. 2003 Oct;77(19):10684-8
references.pmid: 12970455
references.citation: Virology. 1999 Feb 1;254(1):71-80
references.pmid: 9927575
references.citation: Virology. 2005 Oct 10;341(1):91-101
references.pmid: 16061267
references.citation: Adv Virus Res. 2006;66:31-124
references.pmid: 16877059
references.citation: Virology. 2003 Feb 1;306(1):181-95
references.pmid: 12620810
references.citation: Vaccine. 2007 Feb 9;25(8):1513-25
references.pmid: 17126963
references.citation: J Cell Biol. 1999 Jul 12;146(1):113-24
references.pmid: 10402464
references.citation: J Virol. 1991 Oct;65(10):5631-5
references.pmid: 1654459
references.citation: J Virol. 2004 Oct;78(19):10230-7
references.pmid: 15367588
references.citation: J Virol. 2005 Aug;79(15):9458-69
references.pmid: 16014909
references.citation: J Virol. 2006 Sep;80(17):8402-10
references.pmid: 16912291
references.citation: Vaccine. 2008 Jan 30;26(5):664-76
references.pmid: 18096276
references.citation: J Gen Virol. 1967 Jul;1(3):399-402
references.pmid: 6082340
references.citation: Virology. 2006 Jan 5;344(1):48-54
references.pmid: 16364735
references.citation: J Virol. 2006 Oct;80(19):9822-30
references.pmid: 16973586
references.citation: J Virol. 2004 Mar;78(5):2357-66
references.pmid: 14963132
references.citation: J Virol. 2004 May;78(9):4433-43
references.pmid: 15078924
references.citation: Vaccine. 2006 Nov 17;24(47-48):7009-22
references.pmid: 17052815
references.citation: J Virol. 2008 Apr;82(7):3751-68
references.pmid: 18234801
references.citation: J Gen Virol. 1971 Oct;13(1):9-17
references.pmid: 4108676
references.citation: J Gen Virol. 2005 Apr;86(Pt 4):991-1000
references.pmid: 15784892
references.citation: Int J Infect Dis. 2004 Oct;8 Suppl 2:S31-44
references.pmid: 15491873
references.citation: J Virol. 2006 Jan;80(1):51-61
references.pmid: 16352530
references.citation: Vaccine. 2007 Apr 12;25(15):2787-99
references.pmid: 17229505
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5989-94
references.pmid: 16585508
references.citation: J Virol. 2005 Sep;79(17):10988-98
references.pmid: 16103150
references.citation: Am J Epidemiol. 1971 Dec;94(6):612-20
references.pmid: 4332354
references.citation: J Gen Virol. 2002 Dec;83(Pt 12):2915-2931
references.pmid: 12466468
references.citation: J Virol. 2006 Sep;80(18):8899-908
references.pmid: 16940502